IN BRIEF: Uniphar expects yearly profit in line with guidance

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Uniphar PLC - Dublin-based healthcare business focusing on pharmaceutical and medical technology manufacturers - Says gross profit and earnings before interest, tax, depreciation and amortisation are expected to be in line with expectations, adding that its normalised free cashflow conversion has topped medium-term guidance. Achieves a 5% increase in organic gross profit for 2022, driven by ‘organic growth across each division and an outperformance in Supply Chain & Retail,’ Uniphar explains. In 2021 gross profit was €274.5 million.

Chief Executive Officer Ger Rabbette says: ‘Today’s trading update reflects a strong performance by the group in 2022, with organic gross profit growth in excess of 5%. We are confident and remain on track to achieve our strategic objective of doubling Ebitda within 5 years of IPO.’

Uniphar had its initial public offering in July 2019. It debuted with a market capitalisation of €310 million. Looking ahead, firm says it is well-positioned to deliver organic profit growth across all divisions.

Back in August, Uniphar had said pretax profit edged down by 1.9% to €20.3 million for the six months ended on June 30, from €20.7 million a year earlier. Revenue, however, rose 2.8% to €991.8 million from €964.9 million.

Current stock price: last traded on Jan 30 at 300 pence each

12-month change: down 10%

Copyright 2023 Alliance News Ltd. All Rights Reserved.